Who is sponsoring NCT04634435?

NCT04634435 is sponsored by Biohaven Pharmaceuticals, Inc..

What condition does NCT04634435 study?

NCT04634435 studies Multiple Myeloma.

Is NCT04634435 still recruiting?

NCT04634435 is currently completed. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT04634435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Completed Phase 1 Last updated 20 January 2025

What this trial tests

Phase 1 trial testing BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in Multiple Myeloma in 7 participants. Completed in 10 January 2025.

Timeline

21 October 2021

Primary endpoint
10 January 2025

10 January 2025

Quick facts

Lead sponsor	Biohaven Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	21 October 2021
Primary completion	10 January 2025
Estimated completion	10 January 2025
Sites	1 location across United States

Drugs / interventions tested

BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Biohaven Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications.
Terrén I, Orrantia A, Astarloa-Pando G, Amarilla-Irusta A, et al · · 2022 · cited 84× · PMID 35603208 · DOI 10.3389/fimmu.2022.884648
Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
Valeri A, García-Ortiz A, Castellano E, Córdoba L, et al · · 2022 · cited 73× · PMID 35990652 · DOI 10.3389/fimmu.2022.953849
Metabolic changes of Interleukin-12/15/18-stimulated human NK cells.
Terrén I, Orrantia A, Mosteiro A, Vitallé J, et al · · 2021 · cited 67× · PMID 33742092 · DOI 10.1038/s41598-021-85960-6
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A, Tarannum M, Lérias JR, Piccinelli S, et al · · 2024 · cited 41× · PMID 38474415 · DOI 10.3390/cells13050451
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.
Joher N, Matignon M, Grimbert P. · · 2021 · cited 31× · PMID 34093594 · DOI 10.3389/fimmu.2021.688301
Targeting NAD<sup>+</sup> metabolism: dual roles in cancer treatment.
Yong J, Cai S, Zeng Z. · · 2023 · cited 16× · PMID 38116009 · DOI 10.3389/fimmu.2023.1269896
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox.
Xiao J, Zhang T, Gao F, Zhou Z, et al · · 2022 · cited 10× · PMID 36428748 · DOI 10.3390/cancers14225657
Emerging Insights into Memory Natural Killer Cells and Clinical Applications.
Kokiçi J, Preechanukul A, Arellano-Ballestero H, Gorou F, et al · · 2024 · cited 8× · PMID 39599860 · DOI 10.3390/v16111746

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Biohaven Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT04708834 — Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · Phase 3 · terminated
NCT04693351 — Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder · Phase 3 · completed
NCT04641143 — Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder · Phase 3 · completed
NCT03952806 — Study of BHV-3241 in Participants With Multiple System Atrophy · Phase 3 · completed
NCT03829241 — Randomized Trial of Adult Participants With Generalized Anxiety Disorder · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04634435 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biohaven Pharmaceuticals, Inc.
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing